Latham & Watkins advises 4D Molecular Therapeutics on the deal.Astellas Pharma Inc. (TSE: 4503) and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) have announced a license agreement…
Latham & Watkins advises 4D Molecular Therapeutics on the deal.Astellas Pharma Inc. (TSE: 4503) and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) have announced a license agreement…
You must be a Standard 1 Year member to access this content.
…
You must be a Standard 1 Year member to access this content.